Innovent’s IBI363 and IBI343 Data at ESMO Plenary and GI Congress


Innovent Biologics, Inc., a leading biopharmaceutical company, is set to showcase groundbreaking clinical data for two of its novel oncology drug candidates at the prestigious ESMO Virtual Plenary and ESMO Gastrointestinal Cancers Congress 2024 in June. The company will deliver oral presentations highlighting the promising results of IBI363, a first-in-class PD-1/IL-2 bispecific antibody fusion protein, and IBI343, an innovative anti-Claudin18.2 antibody-drug conjugate (ADC).

These presentations underscore Innovent’s commitment to advancing the field of oncology through cutting-edge research and development. The clinical data to be presented at these esteemed medical conferences demonstrate the potential of IBI363 and IBI343 as novel treatment options for cancer patients, further solidifying Innovent’s position as a pioneer in the biopharmaceutical industry.